For what its worth United had Phase 2 Data of OvaRex presented at ASCO in combination with Chemo (for Front-line Ovarian Cancer) and prior phase 2 work in recurrent ovarian cancer in combination with chemo both showing a synergistic immune response.
I am more negative then positive on the Phase 3 IMPACT studies (watchful waiting period administration of OvaRex). I think the data gathered thus far may lead to further studies in using immuno-therapy in conjunction with chemotherapy. It seems a bit counterintuitive to me but perhaps there is more to it if several companies are discovering similar results.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.